GlassScriptPhysician profile
Derrick H Williams
NPI 1780966408
$1,790.74
in general payments reported to CMS, 2019-2025
25 companies · $618 in 2025
The $618 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $114 · 2021: $12.34 · 2022: $85.31 · 2023: $89.94 · 2024: $236 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $943.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $266.59 | 2023-2025 | Vraylar |
| Merck Sharp & Dohme LLC | $238.38 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Novo Nordisk INC | $170.77 | 2019-2024 | Wegovy |
| Pfizer INC. | $136.56 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.93 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $114.09 | 2019-2025 | Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $110.14 | 2019-2025 | |
| Insulet Corporation | $74.27 | 2025 | Omnipod |
| Glaxosmithkline, LLC. | $69.94 | 2019-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $68.97 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.83 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.61 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $38.52 | 2019 | |
| Axsome Therapeutics, INC. | $36.85 | 2025 | Auvelity |
| Exact Sciences Corporation | $35.10 | 2025 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $30.22 | 2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $29.70 | 2025 | Rexulti |
| Amarin Pharma, INC. | $24.35 | 2019 | |
| Amgen INC. | $23.09 | 2019 | |
| Vanda Pharmaceuticals INC. | $22.73 | 2025 | Fanapt |
| Allergan, INC. | $21.03 | 2019 | |
| Azurity Pharmaceuticals, INC. | $18.96 | 2024 | Edarbi |
| Esperion Therapeutics, INC. | $15.46 | 2025 | Nexletol |
| Abiomed | $14.98 | 2025 | |
| Tepha INC | $13.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derrick Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.